Pfizer lung cancer drug fails to beat chemotherapy in late-stage trial

Pfizer’s experimental lung cancer treatment sigvotatug vedotin fell short in a late-stage trial, failing to outperform established chemotherapy. The antibody-drug conjugate had been one of the more closely watched candidates in Pfizer’s oncology pipeline as the company works to rebuild momentum after its pandemic-era revenue receded.

A late-stage miss against standard-of-care chemotherapy narrows the path to approval in that setting and removes a potential growth driver, though such drugs are often tested across multiple tumor types and lines of therapy, leaving room for the program to continue elsewhere. The result is a reminder of how much risk remains concentrated in individual pivotal readouts for large pharmaceutical firms.

Read the source